BioNTech Expands Supervisory Board to Eight, Adds Two Oncology Experts
BioNTech's AGM saw 92% of share capital represented as shareholders approved expanding its Supervisory Board from six to eight members and reappointed three existing board members. Two new directors, Iris Löw-Friedrich and Susanne Schaffert, were elected and Helmut Jeggle was chosen as Supervisory Board chairman.
1. AGM Participation and Resolutions
BioNTech’s 2026 AGM recorded 92% share capital representation, where shareholders approved all proposed agenda items, including the expansion and renewal of Supervisory Board mandates.
2. Supervisory Board Expansion
Shareholders approved increasing the Supervisory Board from six to eight members, electing Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert for their clinical development and oncology commercialization expertise.
3. Mandate Renewals and Leadership Election
Mandates of Helmut Jeggle, Prof. Anja Morawietz and Prof. Rudolf Staudigl were extended, and at the post-AGM board meeting, Helmut Jeggle was elected Supervisory Board Chairman.
4. Continued Oncology Pipeline Focus
Shareholders endorsed BioNTech’s strategic emphasis on its late-stage oncology pipeline alongside ongoing discovery and early-research initiatives to drive long-term innovation.